Benutzer: Gast  Login
Titel:

Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome in Relation to Estimated Glomerular Filtration Rate.

Dokumenttyp:
Article; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Autor(en):
Wöhrle, Jochen; Seeger, Julia; Lahu, Shqipdona; Mayer, Katharina; Bernlochner, Isabell; Gewalt, Senta; Menichelli, Maurizio; Witzenbichler, Bernhard; Hochholzer, Willibald; Sibbing, Dirk; Cassese, Salvatore; Angiolillo, Dominick J; Hemetsberger, Rayyan; Valina, Christian; Kufner, Sebastian; Xhepa, Erion; Hapfelmeier, Alexander; Sager, Hendrik B; Joner, Michael; Richardt, Gert; Laugwitz, Karl-Ludwig; Neumann, Franz Josef; Schunkert, Heribert; Schüpke, Stefanie; Kastrati, Adnan; Ndrepepa, Gjin
Abstract:
OBJECTIVES: The aim of this study was to assess the safety and efficacy of ticagrelor versus prasugrel for patients with acute coronary syndrome (ACS) according to their estimated glomerular filtration rates (eGFRs). BACKGROUND: The outcomes of ticagrelor versus prasugrel in patients with ACS according to eGFR have not been defined. METHODS: Patients (n = 4,012) were categorized into 3 groups: low eGFR (<60 mL/min/1.73 m2), intermediate eGFR (≥60 and <90 mL/min/1.73 m2), and high eGFR (≥90 mL/min/1.73 m2). The primary endpoint was a composite of all-cause death, myocardial infarction, and stroke; the secondary safety endpoint was Bleeding Academic Research Consortium types 3 to 5 bleeding, both at 1 year. RESULTS: Patients with low eGFRs had a higher risk for the primary endpoint compared with patients with intermediate eGFRs (adjusted HR: 1.89; 95% CI: 1.46-2.46]) and those with high eGFRs (adjusted HR: 2.33; 95% CI: 1.57-3.46). A risk excess for low eGFR was also observed for bleeding (adjusted HR: 1.55 [95% CI: 1.12-2.13] vs intermediate eGFR; adjusted HR: 1.59 [95% CI: 1.01-2.50] vs high eGFR). However, eGFR did not affect the relative efficacy and safety of ticagrelor versus prasugrel. In patients with low eGFR, the primary endpoint occurred in 20.5% with ticagrelor and in 14.7% with prasugrel (HR: 1.47; 95% CI: 1.04-2.08; P = 0.029); there was no significant difference in bleeding. CONCLUSIONS: These results show that among patients with ACS, reduction of eGFR is associated with increased risk for ischemic and bleeding events but has no significant impact on the relative efficacy and safety of ticagrelor versus prasugrel. (Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome [ISAR-REACT 5]; NCT01944800).
Zeitschriftentitel:
JACC Cardiovasc Interv
Jahr:
2021
Band / Volume:
14
Heft / Issue:
17
Seitenangaben Beitrag:
1857-1866
Volltext / DOI:
doi:10.1016/j.jcin.2021.06.028
PubMed:
http://view.ncbi.nlm.nih.gov/pubmed/34446390
Print-ISSN:
1936-8798
TUM Einrichtung:
289; Klinik für Herz- und Kreislauferkrankungen im Erwachsenenalter (Prof. Schunkert); Klinik und Poliklinik für Innere Medizin I, Kardiologie; Lehrstuhl für Allgemeinmedizin (Prof. Schneider) (keine SAP-Zuordnung!)
 BibTeX